MA53075A - Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) - Google Patents
Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)Info
- Publication number
- MA53075A MA53075A MA053075A MA53075A MA53075A MA 53075 A MA53075 A MA 53075A MA 053075 A MA053075 A MA 053075A MA 53075 A MA53075 A MA 53075A MA 53075 A MA53075 A MA 53075A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridin
- methyl
- ghrelin
- acyltransferase
- goat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154824 | 2018-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53075A true MA53075A (fr) | 2021-05-12 |
Family
ID=61157050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053075A MA53075A (fr) | 2018-02-02 | 2019-01-28 | Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254688B2 (fr) |
| EP (1) | EP3746451B1 (fr) |
| JP (1) | JP7015396B2 (fr) |
| KR (1) | KR20200116978A (fr) |
| CN (1) | CN111655700B (fr) |
| AU (1) | AU2019215707A1 (fr) |
| BR (1) | BR112020013082A2 (fr) |
| CA (1) | CA3087826A1 (fr) |
| CL (1) | CL2020001907A1 (fr) |
| CO (1) | CO2020009299A2 (fr) |
| CR (1) | CR20200332A (fr) |
| EA (1) | EA202091805A1 (fr) |
| EC (1) | ECSP20050785A (fr) |
| IL (1) | IL276136A (fr) |
| JO (1) | JOP20200190A1 (fr) |
| MA (1) | MA53075A (fr) |
| MX (1) | MX2020008053A (fr) |
| PE (1) | PE20210174A1 (fr) |
| PH (1) | PH12020551168A1 (fr) |
| SG (1) | SG11202006125VA (fr) |
| WO (1) | WO2019149657A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3494120T3 (pl) * | 2016-08-05 | 2021-09-20 | Boehringer Ingelheim International Gmbh | Pochodne oksadiazolopirydyny do zastosowania jako inhibitory o-acylotransferazy greliny (goat) |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| EP3746449B1 (fr) * | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat) |
| PE20210174A1 (es) | 2018-02-02 | 2021-01-29 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
| CN115916789A (zh) | 2020-05-22 | 2023-04-04 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| WO2021233882A1 (fr) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
| WO2023114472A1 (fr) * | 2021-12-16 | 2023-06-22 | Icahn School Of Medicine At Mount Sinai | Composés hétérocycliques en tant qu'agonistes polarisés 5ht2a |
| CN114426516B (zh) * | 2022-02-16 | 2022-11-04 | 安徽有吉医药科技有限公司 | 一种2-氨基-3-溴吡啶的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (fr) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Utilisation de triazolopyrimidines pour combattre les nematodoses de vegetaux |
| JP2009542809A (ja) * | 2006-07-12 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | グレリン受容体アンタゴニストとしての置換ピラゾール |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| DK3567035T3 (da) | 2007-04-11 | 2022-09-05 | Canbas Co Ltd | N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer |
| WO2008141843A1 (fr) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés de quinoléine et de quinazoline substituée par un sulphoximine et de quinazoline en tant qu'inhibiteurs de kinase |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| CN102292348B (zh) | 2008-12-15 | 2015-07-08 | 西兰制药公司 | 胰高血糖素类似物 |
| CA2747155A1 (fr) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Analogues du glucagon |
| PL2370460T3 (pl) | 2008-12-15 | 2014-09-30 | Zealand Pharma As | Analogi glukagonu |
| KR20110126589A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AP2013006671A0 (en) | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
| AP2014007797A0 (en) | 2011-12-23 | 2014-07-31 | Boehringer Ingelheim Int | Glucagon analogues |
| JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (fr) | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Petits inhibiteurs lipopeptidomimétiques de la ghréline o-acyl transférase |
| EP3250569B1 (fr) | 2015-01-30 | 2019-01-09 | Boehringer Ingelheim International GmbH | Inhibiteurs de l'aldostérone synthase |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| ES2936400T3 (es) * | 2015-10-22 | 2023-03-16 | Cavion Inc | Métodos para tratar el síndrome Angelman |
| PL3494120T3 (pl) | 2016-08-05 | 2021-09-20 | Boehringer Ingelheim International Gmbh | Pochodne oksadiazolopirydyny do zastosowania jako inhibitory o-acylotransferazy greliny (goat) |
| RU2751770C2 (ru) * | 2016-08-11 | 2021-07-16 | Селликс Био Прайвет Лимитед | Композиции и способы лечения синдрома раздраженного кишечника |
| US10988487B2 (en) | 2016-08-29 | 2021-04-27 | Merck Sharp & Dohme Corp. | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3746449B1 (fr) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat) |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| PE20210174A1 (es) | 2018-02-02 | 2021-01-29 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
| MX2020008116A (es) | 2018-02-02 | 2020-09-25 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
-
2019
- 2019-01-28 PE PE2020001161A patent/PE20210174A1/es unknown
- 2019-01-28 JO JOP/2020/0190A patent/JOP20200190A1/ar unknown
- 2019-01-28 CN CN201980010416.2A patent/CN111655700B/zh active Active
- 2019-01-28 MX MX2020008053A patent/MX2020008053A/es unknown
- 2019-01-28 JP JP2020541873A patent/JP7015396B2/ja active Active
- 2019-01-28 BR BR112020013082-6A patent/BR112020013082A2/pt not_active Application Discontinuation
- 2019-01-28 EA EA202091805A patent/EA202091805A1/ru unknown
- 2019-01-28 AU AU2019215707A patent/AU2019215707A1/en not_active Abandoned
- 2019-01-28 WO PCT/EP2019/051989 patent/WO2019149657A1/fr unknown
- 2019-01-28 US US16/966,483 patent/US11254688B2/en active Active
- 2019-01-28 MA MA053075A patent/MA53075A/fr unknown
- 2019-01-28 KR KR1020207025417A patent/KR20200116978A/ko unknown
- 2019-01-28 SG SG11202006125VA patent/SG11202006125VA/en unknown
- 2019-01-28 EP EP19702246.0A patent/EP3746451B1/fr active Active
- 2019-01-28 CA CA3087826A patent/CA3087826A1/fr not_active Abandoned
- 2019-01-28 CR CR20200332A patent/CR20200332A/es unknown
-
2020
- 2020-07-19 IL IL276136A patent/IL276136A/en unknown
- 2020-07-21 CL CL2020001907A patent/CL2020001907A1/es unknown
- 2020-07-28 CO CONC2020/0009299A patent/CO2020009299A2/es unknown
- 2020-07-31 PH PH12020551168A patent/PH12020551168A1/en unknown
- 2020-08-24 EC ECSENADI202050785A patent/ECSP20050785A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091805A1 (ru) | 2020-12-16 |
| MX2020008053A (es) | 2020-09-07 |
| CR20200332A (es) | 2020-09-03 |
| PE20210174A1 (es) | 2021-01-29 |
| SG11202006125VA (en) | 2020-07-29 |
| ECSP20050785A (es) | 2020-09-30 |
| CN111655700B (zh) | 2023-07-18 |
| CL2020001907A1 (es) | 2020-10-30 |
| JP7015396B2 (ja) | 2022-02-15 |
| PH12020551168A1 (en) | 2021-05-31 |
| EP3746451A1 (fr) | 2020-12-09 |
| JP2021512113A (ja) | 2021-05-13 |
| KR20200116978A (ko) | 2020-10-13 |
| US11254688B2 (en) | 2022-02-22 |
| CN111655700A (zh) | 2020-09-11 |
| BR112020013082A2 (pt) | 2020-12-01 |
| CO2020009299A2 (es) | 2020-08-21 |
| EP3746451B1 (fr) | 2023-07-12 |
| JOP20200190A1 (ar) | 2020-07-29 |
| AU2019215707A1 (en) | 2020-07-09 |
| IL276136A (en) | 2020-09-30 |
| CA3087826A1 (fr) | 2019-08-08 |
| WO2019149657A1 (fr) | 2019-08-08 |
| US20210053985A1 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53075A (fr) | Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) | |
| MA51774A (fr) | Dérivés de triazolopyrimidine destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) | |
| MA53074A (fr) | Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) | |
| MA56398A (fr) | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA53487A (fr) | Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met | |
| CY1124858T1 (el) | Σαλικυλαμιδια σπειροεπτανιου και σχετικες ενωσεις ως αναστολεις του rock | |
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| MA51327A (fr) | Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar | |
| MA53220A (fr) | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase | |
| MA46531A (fr) | Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds) | |
| MA54091A (fr) | Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr | |
| MA47591A (fr) | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA52940A (fr) | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA54378A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MA53164A (fr) | Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase |